Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial

Abstract Patients with obesity-related heart failure with preserved ejection fraction (HFpEF) display circulatory volume expansion and pressure overload contributing to cardiovascular–kidney end-organ damage. In the SUMMIT trial, patients with HFpEF and obesity were randomized to the long-acting glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonist tirzepatide ( n = 364, 200 women) or placebo ( n = 367, 193 women). As reported separately, tirzepatide decreased cardiovascular death or worsening heart failure. Here, in this mechanistic secondary analysis of the SUMMIT trial, tirzepatide treatment at 52 weeks, as compared with placebo, reduced systolic blood pressure…

• UD
  U.S. Department of Defense

  Award: W81XWH2210245
• EL
  Eli Lilly and Company

  Awards: R01 HL128526, R01 HL162828, U01 HL160226
• NH
  National Heart, Lung, and Blood Institute

  Awards: R01 HL128526, U01 HL160226, HL160226, W81XWH2210245, HL128526, HL162828, R01 HL162828